Biodexa Pharmaceuticals Plc
BDRX
$1.55
-$0.01-0.64%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 51.60K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 51.60K |
| Cost of Revenue | 2.08M | 2.11M | 1.38M | 1.39M | 1.13M |
| Gross Profit | -2.08M | -2.11M | -1.38M | -1.39M | -1.08M |
| SG&A Expenses | 1.13M | 1.14M | 1.28M | 1.29M | 460.20K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -19.90K | -20.20K | -- | -- | -8.70K |
| Total Operating Expenses | 3.19M | 3.24M | 2.66M | 2.68M | 1.58M |
| Operating Income | -3.19M | -3.24M | -2.66M | -2.68M | -1.53M |
| Income Before Tax | -1.63M | -1.66M | -2.17M | -2.18M | -2.25M |
| Income Tax Expenses | -80.00K | -81.30K | -78.80K | -79.30K | -73.30K |
| Earnings from Continuing Operations | -1.55M | -1.58M | -2.09M | -2.10M | -2.18M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.55M | -1.58M | -2.09M | -2.10M | -2.18M |
| EBIT | -3.19M | -3.24M | -2.66M | -2.68M | -1.53M |
| EBITDA | -3.15M | -3.21M | -2.62M | -2.63M | -1.48M |
| EPS Basic | -23.40K | -23.78K | -63.60K | -63.93K | -409.50K |
| Normalized Basic EPS | -1.54 | -1.56 | -4.13 | -4.15 | -16.90 |
| EPS Diluted | -23.40K | -23.78K | -63.60K | -63.93K | -409.50K |
| Normalized Diluted EPS | -1.54 | -1.56 | -4.13 | -4.15 | -16.90 |
| Average Basic Shares Outstanding | 662.50K | 662.50K | 328.10K | 328.10K | 53.30K |
| Average Diluted Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |